Is Ganirelix safe?
Birth anomaly rates similar to agonist cycles
The label pools trial data from 794 women. The most common adverse events were gynecological abdominal pain (4.8%), fetal death (3.7%, which means early pregnancy loss after IVF), headache (3.0%) and OHSS (2.4%). Injection-site reactions were reported in 1.1%. Women must not use it in pregnancy or if they are allergic to GnRH analogs. The label warns of possible allergic reactions, including severe allergy (anaphylaxis), after the first dose. One observational study covered more than 1,000 newborns. It compared birth defect rates after ganirelix cycles with past controls from agonist cycles. The rates were comparable. OHSS comes from the stimulation itself. It is not specific to ganirelix. 14
More on Ganirelix
Citations
- Fyremadel (ganirelix acetate) prescribing information drugs.com
- Fluker 2001, Fertility and Sterility: efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation (North American Ganirelix Study Group) doi.org
- Organon: ganirelix acetate injection product page organonpro.com
- Organon: ganirelix acetate injection prescribing information organon.com
Reference information only, not medical advice. Drawn from the Ganirelix article, fact-checked against the cited sources. No dosing anywhere on this site.